<DOC>
	<DOCNO>NCT01456936</DOCNO>
	<brief_summary>This study conduct assess varenicline bupropion aid smoke cessation treatment subject without establish diagnosis major psychiatric disorder characterize neuropsychiatric safety profile ( pre-specified adverse event ( AEs ) population ) .</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of Varenicline Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders</brief_title>
	<detailed_description />
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Male female cigarette smoker , 18 75 year , motivate stop smoking consider suitable smoking cessation attempt . Smoked average least 10 cigarette per day past year month prior screen visit , exhale carbon monoxide ( CO ) &gt; 10 ppm screening . For Neuropsychiatric cohort subject must proper diagnosis outline protocol . Subjects past current diagnosis one follow disorder : . Psychotic Disorders : Schizophreniform Delusional Disorder Psychotic Disorder NOS b . All Delirium , Dementia , Amnestic Other Cognitive Disorders c. All Substance Induced Disorders ( Other nicotine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>smoke cessation</keyword>
	<keyword>psychiatric disease</keyword>
</DOC>